Biocon has announced its inclusion in SandP's 2024 Sustainability Yearbook for the second consecutive year, based on SandP's 2023 Global Corporate Sustainability Assessment (CSA) of Biocon and Biocon Biologics Limited.
Technology advancements, such as continuous blood glucose monitoring (CGM), have made tracking and controlling blood sugar levels easier. This is much needed because access to robust data can help people optimize blood sugar control
The government plans to introduce a new Production Linked Investment (PLI) scheme for the pharmaceutical sector to increase the production of key chemicals to produce active pharmaceutical ingredients (APIs).
The Indian Council of Medical Research (ICMR) recently announced a series of landmark guidelines and policies to strengthen health services in various regions. From improving early diagnosis and treatment of chronic diseases
The Melanoma Research Alliance (MRA) is the biggest non-profit organization that funds research on melanoma globally. They have expressed their approval of the US Food and Drug Administration's (FDA) decision to authorize Iovance Biotherapeutics....
Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced that it has entered into an exclusive worldwide license agreement with Heidelberg University
Kolkata-based GPT Healthcare, which manages and operates multi-specialty hospitals under the ILS Hospitals brand, has fixed the pay band at Rs. 177- ~ Rs. 186 per share capital with a face value of Rs. 10/- each for initial public offering.
The US Food and Drug Administration (FDA) has announced that drug regulators from Goa and Telangana have joined the group of states overseeing the agency's inspections in India.
New legal guidelines for sampling medicines, cosmetics and medical devices by drug inspectors of central and state drug control agencies will bring much-needed accountability.
Iovance Biotherapeutics, Inc., a biotechnology company focused on the innovation, development and distribution of polyclonal tumor-infiltrating lymphocyte (TIL) cell therapies for cancer patients, has received approval from the US Food and Drug Admin
, CDSCO.jpg)
